Global OTC Dry Eye Drops Market
OTC Dry Eye Drops Market to Surge to USD 8.40 Billion by 2034, Thanks to Rising Prevalence of Dry Eye Syndrome and Technological Advancements
February 05, 2024 04:36 ET | Research and Markets
Dublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "Global OTC Dry Eye Drops Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. With dry eye...
Full Logo - OKYO .jpg
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
January 31, 2024 07:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
22157.jpg
Global Artificial Tear Market Forecast to 2030 Featuring Analysis of J&J Vision Care, Allergan, Alcon, Bausch & Lomb, Santen, URSAPHARM Arzneimittel, and ROHTO Pharmaceutical
January 24, 2024 05:07 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Artificial Tear Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. With...
Full Logo - OKYO .jpg
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
January 08, 2024 07:00 ET | OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...
Full Logo - OKYO .jpg
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023 07:00 ET | OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Global OTC Dry Eye Drops Market
OTC Dry Eye Drops Market Size, Share & Trends Analysis Report 2023-2030: Rising Digital Screen Usage Fuels Global OTC Dry Eye Drops Market Growth
November 20, 2023 08:18 ET | Research and Markets
Dublin, Nov. 20, 2023 (GLOBE NEWSWIRE) -- The "OTC Dry Eye Drops Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Product Type, By Viscosity, By Distribution Channel,...
Global Dry Eye Treatment Devices Market
Dry Eye Treatment Devices Market Trends Analysis Report 2023-2030 with Competitive Analysis of Sight Sciences, Lumenis, ESW Vision, Johnson & Johnson, Alcon, & MiBo Medical Group
October 24, 2023 11:18 ET | Research and Markets
Dublin, Oct. 24, 2023 (GLOBE NEWSWIRE) -- The "Dry Eye Treatment Devices Market Size, Share & Trends Analysis Report By Technology (MGX, Combination (MGX+IPL)), By End-use (Hospitals, Ophthalmic...
Full Logo - OKYO .jpg
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
October 05, 2023 07:00 ET | OKYO Pharma LTD
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the...
Global Refractive Surgery Devices Market
Growing Demand for Painless LASIK Surgeries Drives Opportunities in the Global Refractive Surgery Devices Market 2023-2030
September 28, 2023 07:13 ET | Research and Markets
Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Refractive Surgery Devices Market by Product Type (Aberrometers, Microkeratome, Ophthalmic Laser), Application (Astigmatism, Dry Eyes,...
Full Logo - OKYO .jpg
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
September 08, 2023 07:00 ET | OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...